ROI Calculator: Adding Peptide Therapy to Your Practice

The ROI of adding peptide therapy to a medical practice is substantial: most practices see a 3x to 7x return on their initial investment within 12 months, with break-even typically occurring at month 4 to 7. A solo provider investing $45,000–$65,000 in startup costs can expect to generate $25,000–$50,000 per month in gross revenue once they reach 30–60 active patients. The average peptide therapy patient carries a lifetime value of $8,400 over a 28-month retention period, yielding an LTV-to-CAC ratio of 28:1 to 56:1 — far exceeding most medical specialties. This guide breaks down every cost and revenue variable so you can model the ROI for your specific practice size and growth trajectory.

ROI Snapshot: The Key Numbers

Before we break down the model line by line, here are the three numbers that define the peptide therapy ROI case. Every projection in this guide builds from these empirically grounded figures.

These figures assume a subscription-based billing model, a patient acquisition cost of $150–$300, and an average monthly protocol fee of $300 per patient. Practices using per-visit billing models typically see lower returns due to revenue volatility and higher administrative overhead.

Startup Cost Breakdown

Startup costs vary significantly based on whether you are adding peptide therapy to an existing practice or launching a standalone peptide clinic. The table below covers both scenarios.

The single largest variable is whether you need physical space. A telehealth-first peptide practice can launch for 40–60% less than a brick-and-mortar clinic, with comparable revenue potential in states that allow full telehealth prescribing. See our technology stack guide for the recommended platform architecture.

Monthly Recurring Costs

Once your peptide therapy service is operational, monthly recurring costs fall into fixed and variable categories. Understanding which costs scale with patient volume and which remain constant is critical for projecting margins at different growth stages.

Fixed Monthly Costs (Do Not Scale With Patient Volume)

Variable Costs (Scale With Patient Volume)

Revenue Per Patient Model

Peptide therapy revenue comes from multiple streams per patient. The most successful practices monetize across all four categories rather than relying solely on protocol fees.

We use $300/month as the conservative baseline throughout this guide. Practices that add combination protocols (peptides + TRT or HRT) often see average monthly revenue of $450–$600 per patient, significantly improving ROI timelines.

Lifetime Value Calculation

The 28-month retention figure is based on practices using subscription billing models. Practices on per-visit billing see significantly shorter retention — typically 12–16 months — because patients drop off between appointments when there is no recurring commitment. Subscription billing is not just a billing model; it is a retention strategy that directly impacts LTV by 75–130%.

Patient Acquisition Economics

Patient acquisition cost (CAC) is the second variable that determines ROI. Peptide therapy has favorable acquisition economics because it targets a high-intent patient population willing to pay cash for outcomes-based care.

LTV-to-CAC Ratio

At a blended CAC of $150–$300 and an LTV of $8,400, the LTV:CAC ratio for peptide therapy is 28:1 to 56:1. For context, SaaS companies consider a 3:1 ratio healthy. Most medical practices operate at 5:1 to 10:1. Peptide therapy's ratio is exceptional because patient lifetime values are high and acquisition costs are moderate relative to other cash-pay medical specialties.

This ratio has a practical implication for growth strategy: you can afford to spend aggressively on patient acquisition and still maintain strong unit economics. A practice spending $500 per acquired patient — well above the blended average — still achieves a 16.8:1 LTV:CAC ratio. A well-configured CRM and lead pipeline is essential for tracking these metrics and optimizing acquisition spend across channels.

Break-Even Analysis

Break-even is the month in which cumulative revenue exceeds cumulative costs (startup investment + monthly operating costs). The timeline depends on your patient acquisition velocity and fixed cost structure.

The net contribution per patient ($145) is calculated as average revenue ($300) minus variable costs ($155). Monthly break-even requires enough patients to cover fixed costs: $7,500 / $145 = ~52 patients at the margin, but since patients accumulate over time, the crossover point is reached with approximately 22 patients on the books, which at 6 new patients per month happens around month 4–5.

Break-Even Sensitivity Table

The break-even month is relatively insensitive to patient acquisition speed because fixed costs continue to accumulate each month you are pre-breakeven. The faster you acquire patients, the less total capital you burn before the crossover. At 3 patients per month, you burn approximately $30,000 in total before breaking even. At 8 patients per month, you burn approximately $18,000.

12-Month Projection by Practice Size

The following projections model three practice configurations over 12 months, using conservative assumptions: $300/month average revenue per patient, 5% monthly churn, and blended CAC of $225.

Solo Provider: 12-Month P&L

By month 12, the solo provider has 55 active patients generating $16,500/month in gross revenue. Monthly profitability turns positive around month 11. The cumulative loss of $79,725 includes the original $45,000 startup investment. Full payback of that startup investment typically occurs in months 14–18, after which the practice generates pure profit.

36-Month Projection & Compounding Returns

The real financial power of a peptide therapy practice emerges in years 2 and 3. Once you are past break-even, the compounding effect of a subscription patient base with improving margins creates exponential profit growth.

By month 36, a solo provider who invested $45,000 has generated $178,400 in cumulative net profit — a 396% return on their initial investment. Monthly net profit of $14,800 with 105 active patients represents a mature, sustainable business generating $177,600 per year in net income from peptide therapy alone.

Revenue Scenarios: Solo, 3-Provider, 10-Provider

Practice size changes the ROI equation in two important ways: it increases startup costs and monthly overhead, but it also increases the revenue ceiling and improves margins through economies of scale.

Several patterns emerge from these scenarios. First, larger practices reach break-even faster because their higher patient acquisition velocity overcomes fixed costs more quickly. Second, 36-month ROI improves with scale due to operating leverage — fixed costs are distributed across more patients. Third, the absolute dollars are dramatically different: a 10-provider clinic generates $1.68 million in cumulative net profit over 3 years, compared to $178,400 for a solo provider.

Operating Leverage: Why Margins Improve With Scale

Operating leverage is the mechanism that makes peptide therapy practices increasingly profitable over time. It describes the relationship between fixed costs, variable costs, and revenue as patient volume grows.

Margin Progression by Active Patient Count

Notice that fixed costs only increase marginally from 60 to 150 patients (from $7,500 to $10,000), while revenue triples. This is the operating leverage effect. Each additional patient beyond break-even contributes roughly $145 per month in net profit — and that contribution drops almost entirely to the bottom line.

Subscription Billing & Revenue Predictability

The billing model a practice uses has a disproportionate impact on ROI. Practices that implement subscription billing from day one consistently outperform those using per-visit or per-order billing, for three reasons.

Subscription vs. Per-Visit: Revenue Impact

The subscription model produces 162% more cumulative profit over 36 months for a solo provider — a difference of over $110,000. The improvement comes from three compounding effects: higher monthly revenue per patient, longer retention, and lower revenue variance that reduces the cash reserve needed for operations.

Implementing subscription billing correctly requires a platform that supports recurring charges, automated protocol renewals, and patient self-service for plan management. General-purpose payment processors like Stripe can handle the payments, but the clinical workflow integration — tying billing cycles to prescription renewals, lab schedules, and follow-up cadences — requires purpose-built software.

Technology ROI: How Your Stack Affects the Bottom Line

Your technology platform choice has a measurable impact on peptide therapy ROI through four channels: direct cost, staff efficiency, patient experience (which affects retention), and data visibility (which affects decision-making).

Technology Cost Impact on ROI

The ROI impact of technology choice goes beyond the monthly license fee. Staff time savings of 8–15 hours per week translate to $1,600–$3,000/month in labor costs (at $50/hour for trained medical administrative staff). Higher patient churn from fragmented patient experiences — multiple logins, inconsistent communication, delayed prescription renewals — compounds over time, reducing lifetime value by 15–25%.

For a detailed breakdown of what each technology category costs and how to evaluate platforms, see our complete technology cost guide and recommended technology stack.

Frequently Asked Questions